IS8506A - Nógó-A hlutleysandi ónæmisglóbúlín fyrir meðhöndlun á taugasjúkdómum - Google Patents

Nógó-A hlutleysandi ónæmisglóbúlín fyrir meðhöndlun á taugasjúkdómum

Info

Publication number: IS8506A
Authority: IS; Iceland
Prior art keywords: nogo; treatment; neurological disorders; neutralizing immunoglobulin; immunoglobulin
Prior art date: 2003-12-22

Application number

IS8506A

Other languages

English (en)

Other versions

IS2739B (is

Inventor

Ellis Jonathan Henry

Eon-Duval Alexandre

Grundy Robert Ian

Hussain Farhana

Mcadam Ruth

Plumpton Christopher

Prinjha Rabinder Kumar

Wilson Paul Alexander

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-22

Filing date

2006-06-12

Publication date

2006-06-12

2003-12-22 Priority claimed from GB0329711A external-priority patent/GB0329711D0/en

2003-12-22 Priority claimed from GB0329684A external-priority patent/GB0329684D0/en

2006-06-12 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2006-06-12 Publication of IS8506A publication Critical patent/IS8506A/is

2011-06-15 Publication of IS2739B publication Critical patent/IS2739B/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Psychology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IS8506A 2003-12-22 2006-06-12 Nógó@@@hlutleysandi@ónæmisglóbúlín@fyrir@meðhöndlun@á@taugasjúkdómum IS2739B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0329711A GB0329711D0 (en)	2003-12-22	2003-12-22	Antibodies
GB0329684A GB0329684D0 (en)	2003-12-22	2003-12-22	Method
PCT/GB2004/005325 WO2005061544A2 (en)	2003-12-22	2004-12-20	Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Publications (2)

Publication Number	Publication Date
IS8506A true IS8506A (is)	2006-06-12
IS2739B IS2739B (is)	2011-06-15

Family

ID=34712703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8506A IS2739B (is)	2003-12-22	2006-06-12	Nógó@@@hlutleysandi@ónæmisglóbúlín@fyrir@meðhöndlun@á@taugasjúkdómum

Country Status (27)

Country	Link
US (4)	US7988964B2 (is)
EP (3)	EP1711530B1 (is)
JP (2)	JP2007537145A (is)
KR (1)	KR101150548B1 (is)
AR (1)	AR048912A1 (is)
AT (1)	ATE440866T1 (is)
AU (1)	AU2004303585B2 (is)
BR (1)	BRPI0417959A (is)
CA (1)	CA2549956C (is)
CY (1)	CY1110530T1 (is)
DE (1)	DE602004022871D1 (is)
DK (1)	DK1711530T3 (is)
ES (1)	ES2330444T3 (is)
HR (1)	HRP20090527T1 (is)
IL (1)	IL176206A (is)
IS (1)	IS2739B (is)
MA (1)	MA28289A1 (is)
MX (1)	MXPA06007190A (is)
MY (1)	MY144612A (is)
NO (1)	NO20062767L (is)
NZ (1)	NZ548013A (is)
PL (1)	PL1711530T3 (is)
PT (1)	PT1711530E (is)
RU (1)	RU2362780C2 (is)
SI (1)	SI1711530T1 (is)
TW (1)	TWI329649B (is)
WO (2)	WO2005061544A2 (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002051438A2 (en)	2000-12-22	2002-07-04	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Use of repulsive guidance molecule (rgm) and its modulators
GB0228832D0 (en) *	2002-12-10	2003-01-15	Novartis Ag	Organic compound
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0321997D0 (en) *	2003-09-19	2003-10-22	Novartis Ag	Organic compound
AU2004303585B2 (en)	2003-12-22	2010-12-23	Glaxo Group Limited	NOGO-a neutralising immunoglobulins for treatment of neurological diseases
SG162829A1 (en) *	2005-07-05	2010-07-29	Glaxo Group Ltd	Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
CA2624562A1 (en)	2005-09-30	2007-04-12	Abbott Gmbh & Co. Kg	Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
DK1976877T4 (en) *	2005-11-30	2017-01-16	Abbvie Inc	Monoclonal antibodies to amyloid beta protein and uses thereof
EP1954718B1 (en) *	2005-11-30	2014-09-03	AbbVie Inc.	Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
GB0525662D0 (en) *	2005-12-16	2006-01-25	Glaxo Group Ltd	Immunoglobulins
WO2009124281A2 (en) *	2008-04-04	2009-10-08	The Regents Of The University Of California	Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
US8663635B2 (en)	2006-03-21	2014-03-04	The Regents Of The University Of California	N-cadherin: target for cancer diagnosis and therapy
US20090291976A1 (en) *	2006-06-27	2009-11-26	Peter Andrew Ferchmin	Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
US8455626B2 (en) *	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
ES2435437T3 (es) *	2006-12-07	2013-12-19	Novartis Ag	Anticuerpos antagonistas contra Ephb3
EP2124952A2 (en) *	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Method for the treatment of amyloidoses
US20110105724A1 (en) *	2007-08-16	2011-05-05	Stephanie Jane Clegg	Novel compounds
JP5698534B2 (ja) *	2007-11-02	2015-04-08	ノバルティスアーゲー	改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
JP2011527317A (ja) *	2008-07-11	2011-10-27	グラクソグループリミテッド	Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
US10266585B2 (en)	2009-08-28	2019-04-23	The Board Of Regents Of The Univerity Of Texas System	Methods of treating brain injury
DK2510001T3 (en)	2009-12-08	2016-02-29	Abbvie Deutschland	MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN USED TO TREAT DEGENERATION OF THE RETINAL NERVE FIBER LAYER
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
US8828390B2 (en)	2010-07-09	2014-09-09	Universitat Zurich	Uses of NOGO-A inhibitors and related methods
CN105348387B (zh)	2010-08-14	2020-08-25	Abbvie 公司	β淀粉样蛋白结合蛋白
EP2627357B1 (en) *	2010-10-15	2017-05-03	The Board of Regents of The University of Texas System	Antibodies that bind amyloid oligomers
CN105399831A (zh)	2010-10-29	2016-03-16	伊缪诺金公司	非拮抗性egfr结合分子及其免疫偶联物
CA2815277A1 (en) *	2010-10-29	2012-05-03	Immunogen, Inc.	Novel egfr-binding molecules and immunoconjugates thereof
BR112014012155A2 (pt)	2011-11-21	2017-05-30	Immunogen Inc	método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr
CN104520321A (zh)	2012-01-09	2015-04-15	斯克利普斯研究所	超长互补决定区及其用途
IL305223A (en)	2012-01-27	2023-10-01	Abbvie Inc	The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
WO2014006105A1 (en)	2012-07-05	2014-01-09	Glaxo Group Limited	Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
MX388350B (es)	2015-05-04	2025-03-19	Cytomx Therapeutics Inc	Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
US20180362660A1 (en) *	2016-05-09	2018-12-20	Schickwann Tsai	Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
EA202090247A1 (ru) *	2017-07-14	2020-05-12	Цитомкс Терапьютикс, Инк.	Антитела против cd166 и их применения
JP7362636B2 (ja)	2018-03-05	2023-10-17	ヤンセンファーマシューティカエヌ．ベー．	抗ｐｈｆ－タウ抗体及びその使用
CN112672757A (zh) *	2018-09-25	2021-04-16	中央研究院	抗-唾液酸结合性免疫球蛋白样凝集素的抗体、包括该抗体的药学组合物及其用途
JP7788996B2 (ja) *	2019-10-24	2025-12-19	ノヴァゴーセラピューティクスアーゲー	新規抗Ｎｏｇｏ－Ａ抗体
CA3203749A1 (en) *	2020-12-02	2022-06-09	Agilent Technologies, Inc.	Anti-human cd10 antibodies for use in immunohistochemistry (ihc) protocols to diagnose cancer
CN119768424A (zh) *	2022-08-22	2025-04-04	舒泰神（北京）生物制药股份有限公司	特异性识别Nogo-A的抗体及其应用
CN116693672B (zh) *	2023-06-15	2025-08-08	郑州伊美诺生物技术有限公司	抗3型人副流感病毒单克隆抗体及其制备方法和应用
WO2025006549A2 (en) *	2023-06-28	2025-01-02	University Of Connecticut	Antibodies against immune checkpoint molecules and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3935074A (en) *	1973-12-17	1976-01-27	Syva Company	Antibody steric hindrance immunoassay with two antibodies
US5180820A (en) *	1989-08-30	1993-01-19	Barde Yves Alain	Brain-derived neurotrophic factor
DE69531458T2 (de)	1994-05-27	2004-08-05	Glaxosmithkline S.P.A.	Chinolinderivate als tachykinin nk3 rezeptor antagonisten
CZ304224B6 (cs) *	1998-11-06	2014-01-15	Schwab	Monoklonální protilátka
FR2792199B3 (fr) *	1999-04-13	2001-05-18	Sanofi Sa	Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
US20030113891A1 (en) *	2000-02-11	2003-06-19	Lawrence Blatt	Method and reagent for the inhibition of NOGO and NOGO receptor genes
GB0101313D0 (en) *	2001-01-18	2001-02-28	Glaxo Group Ltd	Assay
WO2003088926A2 (en) *	2002-04-17	2003-10-30	Pharmacia & Upjohn Company Llc	Compositions and method of treating alzheimer’s disease
GB0228832D0 (en) *	2002-12-10	2003-01-15	Novartis Ag	Organic compound
JP2006523708A (ja) *	2003-04-16	2006-10-19	イェールユニバーシティ	アミロイド斑に関連する状態の処置のためのＮｏｇｏレセプターアンタゴニスト
GB0318727D0 (en)	2003-08-08	2003-09-10	Smithkline Beecham Corp	Novel compounds
GB0321997D0 (en)	2003-09-19	2003-10-22	Novartis Ag	Organic compound
AU2004303585B2 (en)	2003-12-22	2010-12-23	Glaxo Group Limited	NOGO-a neutralising immunoglobulins for treatment of neurological diseases

2004
- 2004-12-20 AU AU2004303585A patent/AU2004303585B2/en not_active Ceased
- 2004-12-20 PT PT04806128T patent/PT1711530E/pt unknown
- 2004-12-20 JP JP2006546307A patent/JP2007537145A/ja active Pending
- 2004-12-20 EP EP04806128A patent/EP1711530B1/en not_active Expired - Lifetime
- 2004-12-20 PL PL04806128T patent/PL1711530T3/pl unknown
- 2004-12-20 AR ARP040104811A patent/AR048912A1/es not_active Application Discontinuation
- 2004-12-20 ES ES04806128T patent/ES2330444T3/es not_active Expired - Lifetime
- 2004-12-20 WO PCT/GB2004/005325 patent/WO2005061544A2/en not_active Ceased
- 2004-12-20 JP JP2006544554A patent/JP4901480B2/ja not_active Expired - Fee Related
- 2004-12-20 HR HR20090527T patent/HRP20090527T1/xx unknown
- 2004-12-20 WO PCT/GB2004/005343 patent/WO2005061545A2/en not_active Ceased
- 2004-12-20 CA CA2549956A patent/CA2549956C/en not_active Expired - Fee Related
- 2004-12-20 US US10/583,877 patent/US7988964B2/en not_active Expired - Fee Related
- 2004-12-20 BR BRPI0417959-5A patent/BRPI0417959A/pt not_active IP Right Cessation
- 2004-12-20 AT AT04806128T patent/ATE440866T1/de active
- 2004-12-20 EP EP09168234A patent/EP2213684A3/en not_active Withdrawn
- 2004-12-20 MY MYPI20045254A patent/MY144612A/en unknown
- 2004-12-20 DE DE602004022871T patent/DE602004022871D1/de not_active Expired - Lifetime
- 2004-12-20 SI SI200431272T patent/SI1711530T1/sl unknown
- 2004-12-20 TW TW093139709A patent/TWI329649B/zh not_active IP Right Cessation
- 2004-12-20 MX MXPA06007190A patent/MXPA06007190A/es active IP Right Grant
- 2004-12-20 EP EP04806145A patent/EP1706426A2/en not_active Withdrawn
- 2004-12-20 KR KR1020067014806A patent/KR101150548B1/ko not_active Expired - Fee Related
- 2004-12-20 RU RU2006123481/13A patent/RU2362780C2/ru not_active IP Right Cessation
- 2004-12-20 DK DK04806128T patent/DK1711530T3/da active
- 2004-12-20 NZ NZ548013A patent/NZ548013A/en not_active IP Right Cessation
2005
- 2005-07-06 US US11/177,648 patent/US7780964B2/en not_active Expired - Fee Related
2006
- 2006-06-08 IL IL176206A patent/IL176206A/en not_active IP Right Cessation
- 2006-06-12 IS IS8506A patent/IS2739B/is unknown
- 2006-06-13 NO NO20062767A patent/NO20062767L/no not_active Application Discontinuation
- 2006-07-10 MA MA29178A patent/MA28289A1/fr unknown
2009
- 2009-11-11 CY CY20091101175T patent/CY1110530T1/el unknown
2010
- 2010-08-23 US US12/861,205 patent/US20110054149A1/en not_active Abandoned
2013
- 2013-05-07 US US13/888,764 patent/US20140147435A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2005061544A2 (en)	2005-07-07
EP2213684A3 (en)	2011-05-18
US20110054149A1 (en)	2011-03-03
IL176206A0 (en)	2006-10-05
US7988964B2 (en)	2011-08-02
ES2330444T3 (es)	2009-12-10
EP1706426A2 (en)	2006-10-04
TWI329649B (en)	2010-09-01
EP1711530A2 (en)	2006-10-18
DE602004022871D1 (de)	2009-10-08
MY144612A (en)	2011-10-14
US20060029603A1 (en)	2006-02-09
EP2213684A2 (en)	2010-08-04
CA2549956A1 (en)	2005-07-07
HK1100144A1 (en)	2007-09-07
TW200533680A (en)	2005-10-16
MXPA06007190A (es)	2006-08-23
CY1110530T1 (el)	2015-04-29
KR20060129290A (ko)	2006-12-15
IS2739B (is)	2011-06-15
PT1711530E (pt)	2009-10-22
DK1711530T3 (da)	2009-12-14
AU2004303585A1 (en)	2005-07-07
WO2005061545A2 (en)	2005-07-07
PL1711530T3 (pl)	2010-01-29
US20070065430A1 (en)	2007-03-22
SI1711530T1 (sl)	2010-01-29
JP2008504220A (ja)	2008-02-14
JP4901480B2 (ja)	2012-03-21
US7780964B2 (en)	2010-08-24
WO2005061545A3 (en)	2005-08-18
AR048912A1 (es)	2006-06-14
WO2005061544A3 (en)	2005-08-18
NO20062767L (no)	2006-09-20
ATE440866T1 (de)	2009-09-15
IL176206A (en)	2012-02-29
JP2007537145A (ja)	2007-12-20
HRP20090527T1 (hr)	2009-11-30
CA2549956C (en)	2016-04-12
US20140147435A1 (en)	2014-05-29
RU2362780C2 (ru)	2009-07-27
NZ548013A (en)	2009-04-30
KR101150548B1 (ko)	2012-07-06
EP1711530B1 (en)	2009-08-26
AU2004303585B2 (en)	2010-12-23
MA28289A1 (fr)	2006-11-01
RU2006123481A (ru)	2008-01-27
BRPI0417959A (pt)	2007-03-27

Publication	Publication Date	Title
IS8506A (is)	2006-06-12	Nógó-A hlutleysandi ónæmisglóbúlín fyrir meðhöndlun á taugasjúkdómum
CY2013022I1 (el)	2020-05-29	Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
NO20043237L (no)	2004-08-02	Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
PT2821085T (pt)	2020-07-28	Interferência de arn para o tratamento de distúrbios de ganho de função
NO20053384L (no)	2005-09-15	Benzazepinderivater for behandling av neurologiske forstyrrelser.
DK1660057T3 (da)	2012-08-20	Kombinationsterapi til behandling af neovaskulære øjenlidelser
IS2722B (is)	2011-03-15	1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
IS8516A (is)	2006-06-21	Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum
IS8142A (is)	2005-11-23	Læknislyf gagnleg til meðferðar á verkjum
IS8550A (is)	2006-10-09	Imídasól efnasambönd til meðhöndlunar á taugahrörnunarsjúkdómum
DK1575597T3 (da)	2009-03-16	Anvendelse af rimexolon til behandling af öjentörhed
NL1024499A1 (nl)	2004-04-13	Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen.
IS7099A (is)	2004-01-08	Efnasambönd til að meðhöndla bólgutruflanir
NO20035609L (no)	2004-02-19	Fremgangsmate for kontinuerlig naftabehandling
NO20053678D0 (no)	2005-07-29	Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
NO20053211D0 (no)	2005-06-30	Forbindelser for behandling av metabolske forstyrrelser.
DK1592384T3 (da)	2012-12-17	Cop 1 til behandling af inflammatoriske tarmsygdomme
IS8246A (is)	2006-01-19	Meðferð á taugahrörnunarástandi
NL1026203A1 (nl)	2004-11-16	Verbindingen toepasbaar voor de behandeling van ziekten.
ATE424386T1 (de)	2009-03-15	Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DE502004010131D1 (de)	2009-11-05	Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1611120A4 (en)	2008-04-23	NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
NL1028599A1 (nl)	2005-09-26	Verbindingen voor de behandeling van ziekten.
NL1030418A1 (nl)	2006-05-16	Azabenzoxazolen voor de behandeling van CZS-stoornissen.
IL243687A0 (en)	2016-04-21	For the treatment of multiple myeloma 1–cs antibodies against